The partnership calls for Quintiles to provide commercialization services, including sales support, market intelligence, consulting, regulatory and post-marketing pharmacovigilance in the U.K. and Germany. The companies did not provide specific financial information about the agreement but said they plan to extend the partnership later this year to cover other European countries.
Movetis is a European pharma company focused on the development of drugs used to treat gastrointestinal diseases.
“We are confident that our alliance with Quintiles will help drive our goal of becoming a successful European specialty GI company,” said Movetis CEO Dirk Reyn in a statement. “The launch of Resolor will be a key milestone as we continue to build on our expertise in bringing new GI drugs from discovery to marketing.”
Quintiles launched a revamped brand identity earlier this month, focused on what the company is calling “The New Health”—the rapidly changing pharma industry. This partnership with Movetis is an example of what the company hopes will result from its new branding effort, according to Quintiles.
“This agreement is an example of how leading specialty pharma companies are building partnerships that extend beyond the traditional commercial sales organization model to manage risk, increase productivity, overcome complexity and demonstrate value to stakeholders in the New Health,” said Chris Pepler, senior vice president of global business development and operations for Quintiles.